H Deeg
Medical Oncology · Seattle, WANPI 1184847469
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by CSL Behring at 41.4% of the total. Reporting peaked in 2021 at $24,374 and has fallen 97.0% since, to $733 in 2024.
Across 59 payments — averaging $884.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$22K
- Incyte Corporation$13K
- Amgen$9K
- Novartis$5K
- Bristol Myers Squibb$2K
- Pfizer$1K
Across 189 payments — averaging $14,587 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$2M
- Otsuka Pharmaceutical Co., Ltd.$275K
- Incyte Corporation$236K
- Gilead$156K
- Bristol Myers Squibb$58K
- National Marrow Donor Program$20K
What the payments were for
- Consulting fees$25,76049%
- Speaking & faculty fees$24,84548%
- Travel & lodging$1,1272%
- Food & beverage$4461%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 37 | $21,595 |
| Incyte Corporation | 13 | $13,493 |
| Amgen | 4 | $8,600 |
| Novartis | 2 | $5,240 |
| Bristol Myers Squibb | 1 | $2,250 |
| Pfizer | 2 | $1,005 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,183 in reported general payments places this provider in the 85th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.